ADVA
17.12.2020 09:02:17 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that StarHub is harnessing its FSP 3000 ConnectGuard ™ Optical Layer 1 encryption technology to power the StarHub SDS Secured Service. This fully-managed service enables local enterprises, government agencies and multinational corporations to harness telco-grade encrypted connectivity for their users and systems across multiple locations, with ultra-fast performance and competitive pricing. With StarHub SDS Secured Service, enterprise customers managing highly-confidential and mission-critical information can be assured that all data transfers between their offices, disaster recovery sites and data centers are fully encrypted down to the fiber network level, which is operated and fully owned by StarHub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005032/en/
“In today’s fast-evolving security climate, we are delighted to be partners with ADVA to meet our corporate and government clients’ need for the most comprehensive and effective data security solutions. Operating an extensive private fiber infrastructure, we are in a prime position to help customers quickly and cost-effectively encrypt every bit of data right at the base network level, augmenting their existing firewalls and endpoint protection services to safeguard their mission-critical network connections against unauthorized access,” said Sander Veraar, VP, product management, Enterprise Business Group, StarHub. “With StarHub SDS Secured Service, our customers will enjoy not only robust security features, but also maximum network uptime with automatic traffic re-routing and redundancy as well as 24x7 support.”
The StarHub SDS Secured Service delivers highly-reliable and robustly protected enterprise connectivity on protocols including Ethernet, Fibre Channel and Synchronous Digital Hierarchy (SDH), and with a choice of speeds ranging from 1Gbit/s to 100Gbit/s. Physical layer encryption throughout the network ensures all customer data has the most rigorous defense available. Key security features for customers include protocol-agnostic hardware-based encryption with the lowest latency possible and 100% throughput. Security is also enhanced through simple certificate enrolment protocol-based automation and manual operations, as well as a strictly separated encryption domain manager. What’s more, the solution features automated procedures for authentication, services creation and regular key generation. As the only technology of its kind cleared to transport NATO-restricted data, the ADVA FSP 3000 ConnectGuard™ Optical encryption solution meets the most stringent international standards and regulatory requirements.
“We’re excited to be StarHub’s technology partner as it takes this key step. The StarHub SDS Secured Service offers a major boost to the business community in Singapore, providing the protection as well as the speed and guaranteed uptime needed for the most sensitive and critical data transport,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Our ConnectGuard™ Optical encryption solution is the ideal technology for protecting customer data and trust. Because it encrypts at the transport layer, it does not impact performance. That guarantee of data integrity with regards to latency and throughput is crucial. It’s a major advantage for networks that depend on low latency, such as those interconnecting data centers of financial and government institutions.”
Further information on the StarHub SDS Secured Service is available here: https://adva.li/starhub-sds-secured-service .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About StarHub
StarHub is a leading homegrown Singapore company that delivers world-class communications, entertainment and digital solutions. With our extensive fibre and wireless infrastructure and global partnerships, we bring to people, homes and enterprises quality mobile and fixed services, a broad suite of premium content, and a diverse range of communication solutions. We develop and deliver to corporate and government clients solutions incorporating artificial intelligence, cyber security, data analytics, Internet of Things and robotics. We are committed to conducting our business in a sustainable and environmentally responsible manner. Launched in 2000 and listed on the Singapore Exchange mainboard since 2004, StarHub is a component stock of the SGX Sustainability Leaders Index and the SGX Sustainability Leaders Enhanced Index. Find us at www.starhub.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005032/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom